Products Categories
| CAS No.: | 341-69-5 |
|---|---|
| Name: | ORPHENADRINE HYDROCHLORIDE |
| Molecular Structure: | |
|
|
|
| Formula: | C18H23 N O . Cl H |
| Molecular Weight: | 305.848 |
| Synonyms: | Ethanamine,N,N-dimethyl-2-[(2-methylphenyl)phenylmethoxy]-, hydrochloride (9CI);Ethylamine, N,N-dimethyl-2-[(o-methyl-a-phenylbenzyl)oxy]-, hydrochloride (8CI); (?à)-Orphenadrine hydrochloride;2-(Dimethylamino)ethyl 2-methylbenzhydryl ether hydrochloride; Brocasipal;Disipal; Disipal hydrochloride; Mebedrol; Mefenamin hydrochloride; Mephenamin;Mephenamin hydrochloride; Mephenamine; Mephenamine hydrochloride;N,N-Dimethyl-2-(o-methyl-a-phenylbenzyloxy)ethylamine hydrochloride; NSC 82357; Orfenadrinhydrochloride; Orphenadrine hydrochloride |
| EINECS: | 206-435-4 |
| Density: | 1.014g/cm3 |
| Melting Point: | 156 - 157 C |
| Boiling Point: | 363°Cat760mmHg |
| Flash Point: | 107.1°C |
| Solubility: | Toxicity data
moderate
Stability
Toxicology
Toxicity data |
| Appearance: | white crystalline powder |
| Hazard Symbols: |
|
| Risk Codes: | 22 |
| Safety: | Poison by ingestion, intravenous, intraperitoneal, and subcutaneous routes. Human systemic effects: mydriasis (pupillary dilation), hallucinations, distorted perceptions, pulse rate increase, intracranial pressure increase. An experimental teratogen. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of NOx and HCl. |
| PSA: | 12.47000 |
| LogP: | 4.46460 |
- 483366-12-7(2S,4R)-1-Boc-2-cyano-4-hydroxypyrrolidine
- 361456-36-2METHYL (R)-(+)-ISOCYANATO-3-PHENYLPROPI&
- 5156-58-1N-(1-Benzyl-4-pipperidinyl)-N-phenylpropanamide HCl
- 81281-59-67-Benzylideneaminotheophylline
- 50288-62-5threo-Phenyl-2-piperidyl acetamide
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 47087-37-6Z-D-Glu-OMe
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 68439-39-4Poly(oxy-1,2-ethanediyl), alpha-(2-ethylhexyl)-omega-hydroxy-,
- 852475-26-4MC1568
- 7677-24-9
trimethylsilyl cyanide
- 341-69-5
orphenadrine hydrochloride
A
- 802577-40-8
2-(methyl(2-(phenyl(2-methylphenyl)methoxy)ethyl)amino)acetonitrile
| Conditions | Yield |
|---|---|
| With rose bengal In water at 20℃; for 24h; pH=14; Irradiation; Overall yield = 52%; Overall yield = 1 g; |
- 341-69-5
orphenadrine hydrochloride
B
- 33425-91-1
(R)-N,N-dimethyl-N-{2-[1-(2-methylphenyl)-1-phenylmethoxy]ethyl}amine
| Conditions | Yield |
|---|---|
| With Chiralcel OD-RH column In acetonitrile at 20℃; for 0.116667h; pH=9; Resolution of racemate; |
What can I do for you?
Get Best Price
Chemistry
Chemistry informtion about Orphenadrine Hydrochloride (CAS NO.341-69-5) is:
IUPAC Name: N,N-Dimethyl-2-[(2-Methylphenyl)-Phenylmethoxy]Ethanamine Hydrochloride
Synonyms: 2-Dimethylaminoethyl 2-Methylbenzhydryl Ether Hydrochloride ; 2-Dimethylaminoethyl2-Methylbenzhydryletherhydrochloride ; Bf 5930 ; Bg 5930 ; Brocadisipal ; Brocasipal ; Bs 5930 ; Disipal Hydrochloride
Product Categories: API
MF: C18H24ClNO
MW: 305.84
EINECS: 206-435-4
Flash Point: 107.1 °C
Boiling Point: 363 °C at 760 mmHg
Vapour Pressure: 1.86E-05 mmHg at 25°C
Enthalpy of Vaporization: 60.9 kJ/mol
Storage temp.: 2-8°C
Stability: Stable. Incompatible with strong oxidizing agents.
Following is the molecular structure of Orphenadrine Hydrochloride (CAS NO.341-69-5) is:
Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| child | LDLo | oral | 33mg/kg (33mg/kg) | brain and coverings: increased intracranial pressure | Archiv fuer Toxikologie. Vol. 25, Pg. 76, 1969. |
| guinea pig | LD50 | subcutaneous | 74mg/kg (74mg/kg) | "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 373, 1972. | |
| man | TDLo | oral | 71mg/kg (71mg/kg) | sense organs and special senses: mydriasis (pupillary dilation): eye behavioral: "hallucinations, distorted perceptions" cardiac: pulse rate increase without fall in bp | Human Toxicology. Vol. 4, Pg. 331, 1985. |
| mouse | LD50 | intraperitoneal | 65mg/kg (65mg/kg) | "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 373, 1972. | |
| mouse | LD50 | intravenous | 20mg/kg (20mg/kg) | behavioral: convulsions or effect on seizure threshold behavioral: changes in motor activity (specific assay) behavioral: ataxia | Arzneimittel-Forschung. Drug Research. Vol. 5, Pg. 72, 1955. |
| mouse | LD50 | oral | 100mg/kg (100mg/kg) | behavioral: convulsions or effect on seizure threshold behavioral: changes in motor activity (specific assay) behavioral: ataxia | Arzneimittel-Forschung. Drug Research. Vol. 5, Pg. 72, 1955. |
| mouse | LD50 | subcutaneous | 88mg/kg (88mg/kg) | "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 373, 1972. | |
| rat | LD50 | intraperitoneal | 93mg/kg (93mg/kg) | lungs, thorax, or respiration: respiratory stimulation | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 177, Pg. 28, 1969. |
| rat | LD50 | intravenous | 27500ug/kg (27.5mg/kg) | behavioral: convulsions or effect on seizure threshold behavioral: changes in motor activity (specific assay) behavioral: ataxia | Arzneimittel-Forschung. Drug Research. Vol. 5, Pg. 72, 1955. |
| rat | LD50 | oral | 255mg/kg (255mg/kg) | behavioral: altered sleep time (including change in righting reflex) behavioral: convulsions or effect on seizure threshold behavioral: tremor | Gendai no Rinsho. Vol. 2, Pg. 311, 1968. |
| rat | LD50 | subcutaneous | 230mg/kg (230mg/kg) | behavioral: convulsions or effect on seizure threshold behavioral: ataxia behavioral: changes in motor activity (specific assay) | Arzneimittel-Forschung. Drug Research. Vol. 5, Pg. 72, 1955. |
| women | TDLo | oral | 150mg/kg (150mg/kg) | behavioral: convulsions or effect on seizure threshold behavioral: coma lungs, thorax, or respiration: dyspnea | Archiv fuer Toxikologie. Vol. 23, Pg. 264, 1968. |
Safety Profile
Poison by ingestion, intravenous, intraperitoneal, and subcutaneous routes. Human systemic effects: mydriasis (pupillary dilation), hallucinations, distorted perceptions, pulse rate increase, intracranial pressure increase. An experimental teratogen. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of NOx and HCl.
Hazard Codes:
Xn
Risk Statements:
R22:Harmful if swallowed.
Safety Statements:
S36:Wear suitable protective clothing.
RIDADR: 3249
RTECS: KR6300000
HazardClass: 6.1(b)
PackingGroup: III
Analytical Methods
The citrate salt of orphenadrine is available as Norflex, Banflex, Flexon, and X-Otag, and the hydrochloride salt is available as Disipal and Mephenamin.
In the United States and Canada, orphenadrine citrate is supplied as 100 mg controlled-release tablets, 100 mg immediate-release tablets, and 60 mg immediate-release tablets. Orphenadrine hydrochloride is supplied as 50 and 60 mg tablets, a 10 mg/ml oral solution and 30 mg/ml solution for injection.
Orphenadrine Hydrochloride is also available mixed with aspirin, paracetamol (Anarex), ibuprofen, caffeine, and/or codeine in many places. All Orphenadrine Hydrochloride preparations require a prescription in the United States and the various oral forms are over the counter in Canada; It is also available in many European and Pacific Rim countries (including Australia), by prescription in all of them except Belgium, Mexico and Canada where single-ingredient and combination products are available over the counter. It is available over the counter in the Philippines as Norgesic (35 mg Orphenadrine Citrate/450 mg Paracetamol) and Norgesic Forte (50 mg Orphenadrine Citrate/650 mg Paracetamol) from 3M Pharmaceuticals. Orphenadrine is not available at this time in Japan, Slovenia, Croatia, China, France and Spain.
Specification
Orphenadrine Hydrochloride (CAS NO.341-69-5) is odorless white or almost white crystalline powder. pH (aqueous solution) about 5.5. It is bitter numbing taste. It may be sensitive to prolonged exposure to light and air and it soluble in water. It is incompatible with strong oxidizers. Flash point data for it is not available; however, it is probably combustible.Orphenadrine Hydrochloride has been manufactured at the SAFC Arklow facility since 1988.